Every 10-Q that AUTOLUS THERAPEUTICS PLC (AUTL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AUTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUTL filings page.
Autolus Therapeutics plc reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Net product revenue from AUCATZYL for relapsed or refractory B-cell precursor acute lymphoblastic leukemia rose to $45.7 million from $20.9 million a year earlier, with six‑month product revenue of $71.9 million versus $29.9 million. Revenue now reflects sales in both the U.S. and U.K., while the planned EU launch remains on hold and no EU revenue is expected in 2026.
The company recorded a quarterly net loss of $39.1 million and a six‑month net loss of $110.7 million, narrowing year over year but reducing shareholders’ equity to $74.8 million from $178.1 million at December 31, 2025. Operating activities used $90.4 million of cash in the first half. As of June 30, 2026, Autolus held $171.4 million in cash and cash equivalents and $30.2 million in marketable securities, and later received $75 million from a new Perceptive Advisors notes facility, which management expects will fund operations for at least one year.
The balance sheet includes substantial non‑recourse financing obligations: $284.3 million in liabilities related to future royalties and milestones under the Blackstone and BioNTech arrangements, with an imputed interest rate of up to 28.70%. The company is executing a workforce reduction of about 13%, incurring $4.2 million of severance in the first half to reduce ongoing operating expenses while expanding commercialization of AUCATZYL in the U.S. and U.K.
Autolus Therapeutics plc reports Q1 2026 product revenue of $26.2 million, up from $9.0 million in Q1 2025, driven by AUCATZYL sales in the U.S. and the January 2026 U.K. launch. Despite this growth, the company recorded a net loss of $71.6 million and an operating loss of $59.5 million, with total comprehensive loss of $72.9 million.
Cash, cash equivalents and marketable securities totaled $229.4 million as of March 31, 2026, and management expects these resources to fund operations for at least one year from the statements’ issuance date. Autolus reports liabilities related to future royalties and milestones of $289.2 million, primarily tied to Blackstone and BioNTech funding arrangements.
The company continues to advance obe-cel across additional indications, including lupus nephritis, progressive multiple sclerosis and pediatric B-ALL, and is developing AUTO8 in AL amyloidosis. After quarter end, Autolus approved a restructuring plan, including a workforce reduction of about 13%, targeting annual operating expense savings of approximately $15 million from 2027.
Autolus Therapeutics plc reported the first commercial product revenue following U.S. launch of AUCATZYL: $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025, all recorded in the U.S. via Cardinal Health.
The company recorded a quarterly net loss of $47.9 million and a six-month loss of $118.1 million (basic and diluted loss per share $0.18 and $0.44, respectively). Cash and cash equivalents were $123.8 million and marketable securities $330.5 million at June 30, 2025; management states these balances are sufficient to fund operations for at least 12 months from issuance.
Key balance-sheet items include accounts receivable $26.6 million, inventories $23.9 million (with $2.4 million reserves), and a significant liabilities balance for future royalties and milestones of $250.6 million. The company disclosed FDA approval and U.S. commercial launch of AUCATZYL, MHRA conditional authorization in April 2025, and EU approval in July 2025.